{
    "hands_on_practices": [
        {
            "introduction": "The cornerstone of managing any meningioma is establishing an accurate World Health Organization (WHO) grade, as this determination dictates prognosis and directs all subsequent therapy. This practice challenges you to apply the modern, integrated diagnostic criteria from the 2021 WHO classification, navigating the interplay between classic histology, specific high-risk features, and molecular markers. This exercise  will sharpen your ability to synthesize diverse pathological data to arrive at a definitive grade, a foundational skill in contemporary neuro-oncology.",
            "id": "4494491",
            "problem": "A $62$-year-old woman undergoes gross-total resection of a left frontal convexity extra-axial mass. Histology shows a meningothelial meningioma with whorling and psammoma bodies, without spontaneous necrosis, sheet-like growth, or overt anaplasia. The mitotic count is $2$ per $10$ high-power fields (HPF). A clear interface breach is identified with finger-like infiltration of tumor cells into adjacent cortex accompanied by reactive gliosis, consistent with focal brain invasion. The Ki-$67$ labeling index (MIB-$1$) is $7\\%$. Targeted molecular testing shows wild-type telomerase reverse transcriptase promoter (TERT promoter) and no homozygous deletion of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B). According to the current World Health Organization (WHO) Central Nervous System classification framework, which WHO grade best applies, and why?\n\nChoose the single best answer.\n\nA. WHO grade $1$, because the histology is typical and the mitotic count is low; brain invasion does not alter grade in otherwise typical meningioma\n\nB. WHO grade $2$, because brain invasion alone suffices to upgrade a histologically typical meningioma even with low mitotic activity and no high-risk molecular markers\n\nC. WHO grade $3$, because a Ki-$67$ (MIB-$1$) index above $5\\%$ indicates anaplastic behavior independent of histology\n\nD. WHO grade $3$, because brain invasion combined with Ki-$67$ (MIB-$1$) of $7\\%$ meets criteria for anaplastic meningioma in the absence of high-risk molecular alterations",
            "solution": "The problem statement provides a detailed clinical, histopathological, and molecular profile of a meningioma from a $62$-year-old woman and asks for its classification according to the current World Health Organization (WHO) Central Nervous System (CNS) framework. The current framework is the 5th Edition of the WHO Classification of Tumours of the Central Nervous System, published in $2021$.\n\nFirst, I will summarize the key findings for grading purposes based on the provided data:\n1.  **Histology**: Meningothelial meningioma. This is a common, classic subtype. The absence of spontaneous necrosis and sheet-like growth means it lacks \"atypical\" histological features. It is described as \"otherwise typical\".\n2.  **Mitotic Count**: $2$ per $10$ high-power fields (HPF).\n3.  **Brain Invasion**: Present and confirmed (\"focal brain invasion\").\n4.  **Proliferative Index**: Ki-$67$ (MIB-$1$) is $7\\%$.\n5.  **Molecular Markers**:\n    *   TERT promoter: wild-type (no mutation).\n    *   CDKN2A/B: no homozygous deletion.\n\nNow, I will apply the WHO $2021$ grading criteria for meningiomas.\n\n**WHO Grade $1$ Meningioma**:\nA meningioma is classified as WHO grade $1$ if it has a low proliferative rate, typically a mitotic count of $<4$ per $10$ HPF, and lacks any of the criteria for WHO grade $2$ or $3$. The tumor in this case has a mitotic count of $2$ per $10$ HPF, which is below the threshold for grade $2$ based on mitosis alone. The histology is also consistent with grade $1$. However, the presence of brain invasion must be considered.\n\n**WHO Grade $2$ (Atypical) Meningioma**:\nA meningioma is classified as WHO grade $2$ if it meets at least one of the following criteria:\n*   Mitotic count of $4$–$19$ per $10$ HPF.\n*   Presence of brain invasion.\n*   Presence of at least $3$ of the $5$ following histological features: increased cellularity, small cells with a high nucleus-to-cytoplasm ratio, prominent nucleoli, patternless/sheet-like growth, and foci of spontaneous necrosis.\n\nThe mitotic count in this case is $2$, which is less than the required $4$ for this criterion. The histological description does not support the \"3 of 5\" features criterion. However, the problem explicitly states that \"focal brain invasion\" is present. Brain invasion, defined as the breaching of the pial-glial layer and infiltration into the underlying brain parenchyma, is a standalone criterion for WHO grade $2$. Its presence is sufficient to upgrade an otherwise histologically benign (grade $1$) meningioma to WHO grade $2$.\n\n**WHO Grade $3$ (Anaplastic/Malignant) Meningioma**:\nA meningioma is classified as WHO grade $3$ if it meets at least one of the following criteria:\n*   Mitotic count of $\\geq 20$ per $10$ HPF.\n*   Presence of overt anaplastic features (resembling carcinoma, sarcoma, or melanoma).\n*   Presence of a TERT promoter mutation.\n*   Presence of a homozygous deletion of CDKN2A/B.\n\nThe mitotic count is only $2$, far below the $\\ge 20$ threshold. The histology is described as lacking \"overt anaplasia\". The molecular testing is negative for both TERT promoter mutation and CDKN2A/B homozygous deletion. Therefore, there are no criteria met for WHO grade $3$.\n\n**Role of the Ki-$67$ Index**:\nThe Ki-$67$ labeling index is a measure of cellular proliferation and is an important prognostic marker. An index of $7\\%$ is elevated and may suggest a higher risk of recurrence. However, within the WHO $2021$ classification, the Ki-$67$ index is not a formal diagnostic criterion for assigning a specific grade to meningiomas. It provides supplementary prognostic information but does not by itself determine the grade.\n\n**Conclusion**:\nThe tumor is a meningothelial meningioma with a low mitotic count ($2$ per $10$ HPF). These features, in isolation, would correspond to a WHO grade $1$ tumor. However, the definitive finding of brain invasion is a standalone criterion that, according to the current WHO classification, mandates a diagnosis of WHO grade $2$. The absence of grade $3$ features (high mitotic count, anaplasia, or specific high-risk molecular alterations) precludes a grade $3$ diagnosis. Therefore, the correct classification is WHO grade $2$.\n\nNow, I will evaluate each option.\n\nA. WHO grade $1$, because the histology is typical and the mitotic count is low; brain invasion does not alter grade in otherwise typical meningioma\nThis statement is factually incorrect. The central premise that \"brain invasion does not alter grade\" is in direct conflict with the WHO $2021$ CNS tumor classification, where brain invasion is a definitive criterion for WHO grade $2$. **Incorrect**.\n\nB. WHO grade $2$, because brain invasion alone suffices to upgrade a histologically typical meningioma even with low mitotic activity and no high-risk molecular markers\nThis statement accurately reflects the current WHO grading criteria. The tumor is histologically typical with low mitotic activity, classifying it as grade $1$ on those merits alone. However, the presence of brain invasion is an independent and sufficient criterion to elevate the grade to $2$. The absence of high-risk molecular markers (TERT promoter mutation or CDKN2A/B deletion) confirms it is not grade $3$. **Correct**.\n\nC. WHO grade $3$, because a Ki-$67$ (MIB-$1$) index above $5\\%$ indicates anaplastic behavior independent of histology\nThis statement is incorrect. The Ki-$67$ index is a prognostic marker, not a diagnostic criterion for WHO grading of meningiomas. Furthermore, anaplastic (WHO grade $3$) behavior is defined by specific histological or molecular features as listed above, not by a Ki-$67$ threshold. A value of $7\\%$ does not automatically confer a grade $3$ diagnosis. **Incorrect**.\n\nD. WHO grade $3$, because brain invasion combined with Ki-$67$ (MIB-$1$) of $7\\%$ meets criteria for anaplastic meningioma in the absence of high-risk molecular alterations\nThis statement is incorrect. The grading criteria are not cumulative in this manner. Brain invasion is a criterion for grade $2$, not grade $3$. The Ki-$67$ index is not a grading criterion at all. The combination of a grade $2$ feature and an elevated proliferation index does not satisfy the requirements for a grade $3$ diagnosis. **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "A common clinical dilemma is the management of an incidentally discovered, asymptomatic meningioma. To move beyond subjective assessment, clinicians can quantify a tumor's growth kinetics to guide the decision between active surveillance and pre-emptive intervention. This exercise  asks you to derive and apply the concept of volumetric doubling time ($t_{d}$) from first principles, providing a powerful, objective tool to rationalize management strategies based on a tumor’s observed biological behavior.",
            "id": "4494329",
            "problem": "A patient aged $58$ years has an incidentally discovered convexity meningioma on Magnetic Resonance Imaging (MRI), with an initial volumetric segmentation showing a tumor volume of $10 \\,\\mathrm{ml}$. A follow-up MRI performed at $24$ months shows the tumor volume has increased to $15 \\,\\mathrm{ml}$. Assume that, over this interval, the meningioma’s volumetric growth follows a first-order autonomous law consistent with exponential growth, in which the instantaneous growth rate is proportional to the current volume. Using only this fundamental growth assumption, derive an expression for the volumetric doubling time $t_{d}$ in terms of the measurable quantities at two time points, and then compute $t_{d}$ for this tumor from the given volumes and time interval. Finally, based on the resulting $t_{d}$, discuss qualitatively how such a growth rate would influence management decisions for an otherwise asymptomatic, radiographically benign-appearing meningioma in an adult, explicitly connecting the growth kinetics to surveillance versus intervention reasoning without invoking any pre-memorized specific guideline thresholds.\n\nExpress the final numeric value of $t_{d}$ in months, and round your answer to three significant figures.",
            "solution": "The problem asks for the volumetric doubling time $t_{d}$ under the assumption of exponential growth from first principles. The fundamental base for modeling is the first-order growth law applied to tumor volume $V(t)$:\n$$\n\\frac{dV}{dt} = r \\, V(t),\n$$\nwhere $r$ is the constant specific growth rate. This is a well-tested model for many tumor growth scenarios over finite intervals and serves as a reasonable approximation for meningiomas exhibiting slow, monotonic enlargement.\n\nSolving the differential equation by separation of variables,\n$$\n\\frac{dV}{V} = r \\, dt \\quad \\Rightarrow \\quad \\int_{V(0)}^{V(t)} \\frac{dV'}{V'} = \\int_{0}^{t} r \\, dt',\n$$\ngives\n$$\n\\ln\\!\\left(\\frac{V(t)}{V(0)}\\right) = r \\, t,\n$$\nand thus the exponential solution\n$$\nV(t) = V(0)\\,\\exp(r t).\n$$\n\nGiven two measurements $V_{0}$ at $t=0$ and $V_{1}$ at $t=T$, the specific growth rate $r$ is obtained directly from\n$$\n\\ln\\!\\left(\\frac{V_{1}}{V_{0}}\\right) = r \\, T \\quad \\Rightarrow \\quad r = \\frac{1}{T}\\,\\ln\\!\\left(\\frac{V_{1}}{V_{0}}\\right).\n$$\n\nThe volumetric doubling time $t_{d}$ is defined as the time required for the volume to increase by a factor of $2$ under the same growth law. By definition, starting from any volume $V$, the doubling condition is\n$$\nV \\,\\exp(r \\, t_{d}) = 2 V \\quad \\Rightarrow \\quad \\exp(r \\, t_{d}) = 2 \\quad \\Rightarrow \\quad t_{d} = \\frac{\\ln(2)}{r}.\n$$\nSubstituting the expression for $r$ obtained from two time points yields\n$$\nt_{d} = \\frac{\\ln(2)}{\\frac{1}{T}\\,\\ln\\!\\left(\\frac{V_{1}}{V_{0}}\\right)} = T \\, \\frac{\\ln(2)}{\\ln\\!\\left(\\frac{V_{1}}{V_{0}}\\right)}.\n$$\n\nWe now apply the given values: initial volume $V_{0} = 10 \\,\\mathrm{ml}$, follow-up volume $V_{1} = 15 \\,\\mathrm{ml}$, and interval $T = 24$ months. Keeping symbolic expressions until the final step, we compute\n$$\nt_{d} = 24 \\, \\frac{\\ln(2)}{\\ln\\!\\left(\\frac{15}{10}\\right)} = 24 \\, \\frac{\\ln(2)}{\\ln(1.5)}.\n$$\nTo produce the requested numeric value in months and to three significant figures, we evaluate:\n$$\n\\ln(2) \\approx 0.693147, \\quad \\ln(1.5) \\approx 0.405465,\n$$\nso\n$$\nt_{d} \\approx 24 \\times \\frac{0.693147}{0.405465} \\approx 24 \\times 1.70951 \\approx 41.0283 \\text{ months}.\n$$\nRounded to three significant figures, the volumetric doubling time is\n$$\n41.0 \\text{ months}.\n$$\n\nManagement interpretation linked to growth kinetics: In meningiomas, especially those suspected to be World Health Organization (WHO) grade $1$ by imaging characteristics and in the absence of symptoms, exponential growth with a doubling time on the order of several years indicates indolent behavior. A $t_{d}$ of approximately $41$ months reflects slow volumetric expansion. For an asymptomatic adult with a radiographically benign lesion, such a slow growth rate generally supports continued active surveillance with periodic imaging rather than immediate intervention, provided there are no high-risk features such as significant peritumoral edema, mass effect on critical structures, or evidence of rapid acceleration. Surveillance intervals might reasonably be spaced to detect meaningful change (for example, annual to biennial), with the understanding that management should be re-evaluated if the growth kinetics shorten (smaller $t_{d}$), new symptoms emerge, or imaging suggests higher-grade behavior. The growth law connection is explicit: a larger $t_{d}$ implies a smaller $r$, indicating slower progression, which decreases the urgency for treatment in an otherwise stable clinical context; conversely, a smaller $t_{d}$ would increase consideration for earlier intervention. This reasoning aligns with general principles of neuro-oncology and clinical decision-making, without reliance on memorized thresholds.",
            "answer": "$$\\boxed{41.0}$$"
        },
        {
            "introduction": "This capstone practice simulates a complex, high-stakes clinical scenario that reflects the cutting edge of neuro-oncology. It demonstrates how a single molecular finding can completely upend an initial diagnosis based on histology, mandating a radical shift in the entire treatment paradigm. Successfully navigating this problem  requires you to integrate knowledge across neuropathology, molecular diagnostics, and radiation oncology to formulate a comprehensive, evidence-based management plan for a high-risk meningioma.",
            "id": "4494362",
            "problem": "A $62$-year-old person underwent gross total resection by Simpson grade II for a right frontoparietal convexity meningioma. Histology shows a World Health Organization (WHO) grade $1$ meningioma without brain invasion and a mitotic count of $<4$ per $10$ high-power fields. Targeted molecular profiling reveals a Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) homozygous deletion. Immediate postoperative magnetic resonance imaging (MRI) shows no residual nodular enhancement; the resection cavity abuts the superior sagittal sinus but is $>5$ $\\mathrm{mm}$ from the optic apparatus. The treating team had initially planned observation based on histology, but now requests a revision of the diagnosis and an adjuvant radiotherapy (RT) plan. Using the principles of the WHO Central Nervous System classification, established risk-group frameworks in meningioma, and radiobiologic reasoning based on the linear-quadratic model for comparing fractionation schedules, determine the most appropriate integrated management decision that both correctly assigns grade and specifies an adjuvant RT approach that prioritizes local control while respecting typical organs-at-risk constraints. Consider tumor control requirements for high-risk meningioma, the need to encompass the operative bed and involved dura, and the comparative biological effectiveness of candidate dose-fractionation schemes. Choose the single best option.\n\nA. Retain WHO grade $1$; no adjuvant RT; MRI surveillance only.\n\nB. Upgrade to WHO grade $3$; deliver adjuvant Intensity-Modulated Radiotherapy (IMRT) to a clinical target volume including the resection cavity and involved adjacent dura with a $1$ $\\mathrm{cm}$ margin and a planning target volume (PTV) expansion of $3$–$5$ $\\mathrm{mm}$, prescribing $60$ $\\mathrm{Gy}$ in $30$ fractions to the high-risk PTV while constraining the optic apparatus to $\\leq54$ $\\mathrm{Gy}$ equivalent dose in $2$ $\\mathrm{Gy}$ fractions.\n\nC. Upgrade to WHO grade $2$; deliver adjuvant IMRT to $54$ $\\mathrm{Gy}$ in $30$ fractions to the operative bed and dural tail with a $5$ $\\mathrm{mm}$ PTV margin; no explicit organs-at-risk constraints required given the distance from optic apparatus.\n\nD. Retain WHO grade $1$; deliver single-fraction stereotactic radiosurgery (SRS) to the resection cavity at $14$ $\\mathrm{Gy}$, omitting fractionated RT because histology is benign.\n\nE. Upgrade to WHO grade $3$; deliver hypofractionated RT at $50.4$ $\\mathrm{Gy}$ in $28$ fractions to reduce late toxicity, accepting lower biological dose because of presumed radiosensitivity with CDKN$2\\mathrm{A}/2\\mathrm{B}$ loss.",
            "solution": "The core of this problem rests on two key steps: (1) correctly re-diagnosing and grading the meningioma by integrating the molecular findings, and (2) determining the appropriate adjuvant therapy based on the revised diagnosis.\n\n### Principle 1: Tumor Grading based on 2021 WHO Classification\nThe initial histologic assessment indicates a WHO grade $1$ meningioma. However, the 5th Edition of the WHO Classification of CNS Tumours (published in 2021) introduced molecular criteria that can override a histologic grade. One of the most significant changes for meningiomas is the following:\n\n*   **Homozygous deletion of *CDKN2A/B* is now a sufficient criterion, in and of itself, to classify a meningioma as anaplastic meningioma, WHO grade 3.**\n\nThis criterion applies regardless of the histologic appearance. Therefore, despite the histologically benign features (low mitotic index, no brain invasion), the discovery of a *CDKN2A/B* homozygous deletion compels a diagnostic upgrade to WHO grade $3$.\n\nThis finding immediately invalidates any management plan based on a WHO grade $1$ or grade $2$ diagnosis.\n\n### Principle 2: Management of WHO Grade 3 Meningioma\nWHO grade $3$ (anaplastic) meningiomas are malignant neoplasms with a high propensity for aggressive local recurrence and a poor prognosis. The standard of care involves maximally safe surgical resection followed by mandatory adjuvant radiotherapy (RT). Observation is not an acceptable strategy, even after a gross total resection (Simpson I/II), due to the nearly universal risk of recurrence. The patient's surgery was a Simpson grade II resection, which involves coagulation of the dural attachment and carries a higher risk of recurrence than a Simpson grade I resection (which includes excision of the dural attachment). This further strengthens the indication for adjuvant RT.\n\nFor a WHO grade $3$ meningioma, a high radiation dose is required to maximize the probability of local tumor control. The standard dose is typically $60$ $\\mathrm{Gy}$ delivered in $30$ daily fractions of $2$ $\\mathrm{Gy}$.\n\n### Principle 3: Radiotherapy Planning and Radiobiology\nAdjuvant radiotherapy must be planned meticulously to cover the regions at risk for recurrence while sparing nearby critical normal tissues (Organs at Risk, OARs).\n\n*   **Target Volume Delineation**: The Clinical Target Volume (CTV) must encompass the entire postoperative resection cavity and the involved dura, often with a margin of $1$ to $2$ $\\mathrm{cm}$ to account for microscopic tumor infiltration. The Planning Target Volume (PTV) is an expansion of the CTV (typically by $3$ to $5$ $\\mathrm{mm}$) to account for uncertainties in daily patient setup and internal organ motion.\n*   **Dose Prescription**: As stated, $60$ $\\mathrm{Gy}$ in $30$ fractions is the standard of care for adjuvant treatment of WHO grade $3$ meningioma.\n*   **OAR Constraints**: Critical structures must be identified and their received dose must be kept below established tolerance limits. For a frontoparietal lesion, relevant OARs include the optic apparatus (chiasm, nerves), brainstem, and normal brain tissue. The tolerance dose of the optic apparatus to conventionally fractionated radiation is a maximum point dose of $54$ $\\mathrm{Gy}$. Any treatment plan must respect this limit. Modern techniques like Intensity-Modulated Radiotherapy (IMRT) are used to create a highly conformal dose distribution that achieves this goal.\n\n### Option-by-Option Analysis\n\n**A. Retain WHO grade 1; no adjuvant RT; MRI surveillance only.**\n*   **Evaluation**: This option fails to incorporate the molecular data (*CDKN2A/B* deletion), leading to an incorrect diagnosis (WHO grade $1$ instead of $3$). Consequently, it proposes an inadequate management plan (observation) for a highly aggressive tumor.\n*   **Verdict**: **Incorrect**.\n\n**B. Upgrade to WHO grade 3; deliver adjuvant Intensity-Modulated Radiotherapy (IMRT) to a clinical target volume including the resection cavity and involved adjacent dura with a $1$ $\\mathrm{cm}$ margin and a planning target volume (PTV) expansion of $3$–$5$ $\\mathrm{mm}$, prescribing $60$ $\\mathrm{Gy}$ in $30$ fractions to the high-risk PTV while constraining the optic apparatus to $\\leq54$ $\\mathrm{Gy}$ equivalent dose in $2$ $\\mathrm{Gy}$ fractions.**\n*   **Evaluation**: This option correctly upgrades the diagnosis to WHO grade $3$ based on the *CDKN2A/B* deletion. The proposed management is fully consistent with the standard of care:\n    *   **Technique**: IMRT is appropriate.\n    *   **Target Volume**: The CTV and PTV definitions are standard and appropriate for high-grade meningioma.\n    *   **Dose/Fractionation**: $60$ $\\mathrm{Gy}$ in $30$ fractions ($2$ $\\mathrm{Gy}$/fraction) is the standard, evidence-based regimen for WHO grade $3$ meningiomas.\n    *   **OAR Constraint**: It correctly identifies the critical optic apparatus tolerance of $54$ $\\mathrm{Gy}$ and includes it as a planning constraint, which is essential for safe delivery of RT. The fact that the target is $>5$ $\\mathrm{mm}$ away makes this constraint achievable.\n*   **Verdict**: **Correct**.\n\n**C. Upgrade to WHO grade 2; deliver adjuvant IMRT to $54$ $\\mathrm{Gy}$ in $30$ fractions to the operative bed and dural tail with a $5$ $\\mathrm{mm}$ PTV margin; no explicit organs-at-risk constraints required given the distance from optic apparatus.**\n*   **Evaluation**: This option has multiple, serious flaws.\n    *   **Grading**: The upgrade to WHO grade $2$ is incorrect; the molecular finding mandates grade $3$.\n    *   **Dose**: $54$ $\\mathrm{Gy}$ is a standard dose for WHO grade $2$ meningiomas, but it is suboptimal for a WHO grade $3$ tumor.\n    *   **OAR Constraint**: The statement that \"no explicit organs-at-risk constraints required\" is a grave error and represents a violation of fundamental radiation safety principles. Dose to all OARs must always be evaluated and minimized, regardless of distance.\n*   **Verdict**: **Incorrect**.\n\n**D. Retain WHO grade 1; deliver single-fraction stereotactic radiosurgery (SRS) to the resection cavity at $14$ $\\mathrm{Gy}$, omitting fractionated RT because histology is benign.**\n*   **Evaluation**: This option is incorrect for several reasons.\n    *   **Grading**: It fails to upgrade the diagnosis to WHO grade $3$.\n    *   **Treatment Modality**: SRS to a large postsurgical cavity is generally inappropriate, especially for a diffusely infiltrating high-grade tumor. Fractionated RT is the standard to safely treat the required large volume.\n    *   **Dose**: A single fraction of $14$ $\\mathrm{Gy}$ is radiobiologically insufficient for controlling a WHO grade $3$ malignancy. The biologically effective dose (BED) is far lower than that of $60$ $\\mathrm{Gy}$ in $30$ fractions. For a tumor with an assumed $\\alpha/\\beta$ of $10$ $\\mathrm{Gy}$, the BED for $14$ $\\mathrm{Gy}$ SRS is $14 \\times (1 + \\frac{14}{10}) = 33.6$ $\\mathrm{Gy}_{10}$, whereas for $60$ $\\mathrm{Gy}$ in $30$ fractions, the BED is $60 \\times (1 + \\frac{2}{10}) = 72$ $\\mathrm{Gy}_{10}$.\n*   **Verdict**: **Incorrect**.\n\n**E. Upgrade to WHO grade 3; deliver hypofractionated RT at $50.4$ $\\mathrm{Gy}$ in $28$ fractions to reduce late toxicity, accepting lower biological dose because of presumed radiosensitivity with CDKN$2\\mathrm{A}/2\\mathrm{B}$ loss.**\n*   **Evaluation**: This option correctly upgrades the grade but proposes a flawed RT plan.\n    *   **Dose/Fractionation**: The proposed regimen of $50.4$ $\\mathrm{Gy}$ in $28$ fractions results in a dose per fraction of $1.8$ $\\mathrm{Gy}$. This is conventional fractionation, not \"hypofractionated\" (which implies fractions $>2$ $\\mathrm{Gy}$). The total dose of $50.4$ $\\mathrm{Gy}$ is inadequate for a WHO grade $3$ tumor.\n    *   **Rationale**: The reason given for dose reduction—\"presumed radiosensitivity with CDKN$2\\mathrm{A}/2\\mathrm{B}$ loss\"—is speculative and not supported by clinical evidence. Standard practice does not involve de-escalating therapy for a marker associated with increased aggression. The logical response to a high-risk feature is treatment intensification, not reduction.\n*   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}